Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., de Castro, C. M., Deeg, H. J., DeZern, A. E., Dinner, S., Foucar, C., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Jonas, B. A., Keel, S., Madanat, Y., Maness, L. J., Mangan, J., McCurdy, S., McMahon, C., Patel, B., Reddy, V. V., Sallman, D. A., Shallis, R., Shami, P. J., Thota, S., Varshavsky-Yanovsky, A. N., Westervelt, P., Hollinger, E., Shead, D. A., Hochstetler, C. 2022; 20 (2): 106-117

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

View details for DOI 10.6004/jnccn.2022.0009

View details for PubMedID 35130502